83_FR_48504 83 FR 48319 - National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

83 FR 48319 - National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 185 (September 24, 2018)

Page Range48319-48319
FR Document2018-20666

Federal Register, Volume 83 Issue 185 (Monday, September 24, 2018)
[Federal Register Volume 83, Number 185 (Monday, September 24, 2018)]
[Notices]
[Page 48319]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-20666]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Arthritis and Musculoskeletal and Skin 
Diseases; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Arthritis and 
Musculoskeletal and Skin Diseases Special Emphasis Panel; T32 
Institutional Training Grants.
    Date: October 10, 2018.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD 
20852.
    Contact Person: Nakia C. Brown, Ph.D., Scientific Review 
Officer, 6701 Democracy Blvd., RM 816, Bethesda, MD 20892, 301-827-
4905, [email protected].

    Name of Committee: Arthritis and Musculoskeletal and Skin 
Diseases Initial Review Group; Arthritis and Musculoskeletal and 
Skin Diseases Clinical Trials Review Committee.
    Date: October 16-17, 2018.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Garden Inn, 7301 Waverly Street, Bethesda, MD 
20814.
    Contact Person: Nakia C. Brown, Ph.D., NIAMS/Scientific Review 
Officer, 6701 Democracy Blvd., RM 816, Bethesda, MD 20892, 301-827-
4905, [email protected].

    Name of Committee: National Institute of Arthritis and 
Musculoskeletal and Skin Diseases Special Emphasis Panel; AMSC 
Member Conflict.
    Date: October 29, 2018.
    Time: 10:00 a.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Democracy One, 6701 Democracy Blvd., Bethesda, MD 20892.
    Contact Person: Yasuko Furumoto, Ph.D., NIAMS/Scientific Review 
Officer, 6701 Democracy Blvd., RM 816, Bethesda, MD 20892, 301-451-
6520, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, 
Arthritis, Musculoskeletal and Skin Diseases Research, National 
Institutes of Health, HHS)

    Dated: September 18, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-20666 Filed 9-21-18; 8:45 am]
 BILLING CODE 4140-01-P



                                                                        Federal Register / Vol. 83, No. 185 / Monday, September 24, 2018 / Notices                                                  48319

                                              would benefit from harmonization,                       DEPARTMENT OF HEALTH AND                              Musculoskeletal and Skin Diseases Research,
                                              consistency, clarity, simplification, and/              HUMAN SERVICES                                        National Institutes of Health, HHS)
                                              or coordination.                                                                                                Dated: September 18, 2018.
                                                                                                      National Institutes of Health                         Sylvia L. Neal,
                                                 The SACHRP meeting will open to the
                                              public at 8:30 a.m., on Tuesday, October                National Institute of Arthritis and                   Program Analyst, Office of Federal Advisory
                                              16, 2018, followed by opening remarks                                                                         Committee Policy.
                                                                                                      Musculoskeletal and Skin Diseases;
                                              from Dr. Jerry Menikoff, Director of                    Notice of Closed Meetings                             [FR Doc. 2018–20666 Filed 9–21–18; 8:45 am]
                                              OHRP and Dr. Stephen Rosenfeld,                                                                               BILLING CODE 4140–01–P
                                              SACHRP Chair.                                             Pursuant to section 10(d) of the
                                                                                                      Federal Advisory Committee Act, as
                                                 The SAS and SOH subcommittees                        amended, notice is hereby given of the                DEPARTMENT OF HEALTH AND
                                              will present their recommendations                      following meetings.                                   HUMAN SERVICES
                                              regarding the description of ‘‘key                        The meetings will be closed to the
                                              information,’’ as required by the revised               public in accordance with the                         National Institutes of Health
                                              Common Rule at § 46.116(a)(5)(i). This                  provisions set forth in sections
                                              will be followed by a discussion of                     552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,            Government-Owned Inventions;
                                              recommendations of the interpretation                   as amended. The grant applications and                Availability for Licensing
                                              of the revised Common Rule’s                            the discussions could disclose                        AGENCY:    National Institutes of Health,
                                              exemptions § 46.104(d)(1) and (2) for                   confidential trade secrets or commercial              HHS.
                                              HHS funded research. Lastly, the                        property such as patentable material,                 ACTION:   Notice.
                                              committee will continue its July                        and personal information concerning
                                              discussions on the Office of Inspector                  individuals associated with the grant                 SUMMARY:   The invention listed below is
                                              General Report, July 7, 2017: ‘‘OHRP                    applications, the disclosure of which                 owned by an agency of the U.S.
                                              Generally Conducted Its Compliance                      would constitute a clearly unwarranted                Government and is available for
                                              Activities Independently, But Changes                   invasion of personal privacy.                         licensing to achieve expeditious
                                              Would Strengthen Its Independence.’’                      Name of Committee: National Institute of            commercialization of results of
                                                 The Wednesday, October 17, meeting                   Arthritis and Musculoskeletal and Skin                federally-funded research and
                                              will begin at 8:30 a.m. The SAS                         Diseases Special Emphasis Panel; T32                  development. Foreign patent
                                              subcommittee will present and discuss                   Institutional Training Grants.                        applications are filed on selected
                                              recommendations on the interpretation                     Date: October 10, 2018.                             inventions to extend market coverage
                                                                                                        Time: 8:00 a.m. to 5:00 p.m.                        for companies and may also be available
                                              of ‘‘reasonably available’’ at § 46.408(b),               Agenda: To review and evaluate grant
                                              as well as discuss issues surrounding                                                                         for licensing.
                                                                                                      applications.
                                              payment of subjects for participation in                  Place: Canopy by Hilton, 940 Rose Avenue,           FOR FURTHER INFORMATION CONTACT:
                                              research. Modifications to the previous                 North Bethesda, MD 20852.                             Yogikala Prabhu, Ph.D., 301–761–7789;
                                              day’s work will be discussed and                          Contact Person: Nakia C. Brown, Ph.D.,              prabhuyo@niaid.nih.gov. Licensing
                                              finalized. The meeting will adjourn at                  Scientific Review Officer, 6701 Democracy             information and copies of the patent
                                              approximately 4:00 p.m., October 17,                    Blvd., RM 816, Bethesda, MD 20892, 301–               applications listed below may be
                                                                                                      827–4905, brownnac@mail.nih.gov.                      obtained by communicating with the
                                              2018.
                                                                                                        Name of Committee: Arthritis and                    indicated licensing contact at the
                                                 Time for public comment sessions                     Musculoskeletal and Skin Diseases Initial             Technology Transfer and Intellectual
                                              will be allotted both days. On-site                     Review Group; Arthritis and Musculoskeletal           Property Office, National Institute of
                                              registration is required for participation              and Skin Diseases Clinical Trials Review
                                                                                                      Committee.                                            Allergy and Infectious Diseases, 5601
                                              in the live public comment session.
                                                                                                        Date: October 16–17, 2018.                          Fishers Lane, Rockville, MD 20852; tel.
                                              Note that public comment must be
                                                                                                        Time: 8:00 a.m. to 5:00 p.m.                        301–496–2644. A signed Confidential
                                              relevant to topics currently being                                                                            Disclosure Agreement will be required
                                                                                                        Agenda: To review and evaluate grant
                                              addressed by the SACHRP. Individuals                    applications.                                         to receive copies of unpublished patent
                                              submitting written statements as public                   Place: Hilton Garden Inn, 7301 Waverly              applications.
                                              comment should email or fax their                       Street, Bethesda, MD 20814.                           SUPPLEMENTARY INFORMATION:
                                              comments to SACHRP at SACHRP@                             Contact Person: Nakia C. Brown, Ph.D.,
                                                                                                                                                            Technology description follows.
                                              hhs.gov at least five business days prior               NIAMS/Scientific Review Officer, 6701
                                              to the meeting.                                         Democracy Blvd., RM 816, Bethesda, MD                 A New Class of Immunomodulatory
                                                                                                      20892, 301–827–4905, brownnac@                        Drugs for Multiple Sclerosis
                                                 Public attendance at the meeting is                  mail.nih.gov.
                                              limited to space available. Individuals                   Name of Committee: National Institute of               Description of Technology: Multiple
                                              who plan to attend and need special                     Arthritis and Musculoskeletal and Skin                sclerosis (MS) is an autoimmune disease
                                              assistance, such as sign language                       Diseases Special Emphasis Panel; AMSC                 caused by activated autoimmune T
                                              interpretation or other reasonable                      Member Conflict.                                      lymphocytes in patients resulting in
                                              accommodations, should notify one of                      Date: October 29, 2018.                             inflammatory demyelination in the
                                              the designated SACHRP points of                           Time: 10:00 a.m. to 2:00 p.m.                       central nervous system. Current
                                              contact at the address/phone number                       Agenda: To review and evaluate grant                treatments are focused on functional
                                              listed above at least one week prior to                 applications.                                         control of these activated autoimmune T
                                                                                                        Place: Democracy One, 6701 Democracy
                                              the meeting.                                                                                                  cells, but these treatments are non-
amozie on DSK3GDR082PROD with NOTICES1




                                                                                                      Blvd., Bethesda, MD 20892.
                                                                                                        Contact Person: Yasuko Furumoto, Ph.D.,             specific T cell inhibitors and have
                                                Dated: September 14, 2018.
                                                                                                      NIAMS/Scientific Review Officer, 6701                 serious, sometimes fatal side effects. A
                                              Julia G. Gorey,                                                                                               specific therapy aimed at eliminating
                                                                                                      Democracy Blvd., RM 816, Bethesda, MD
                                              Executive Director, Secretary’s Advisory                20892, 301–451–6520, yasuko.furumoto@                 these autoimmune T cells through
                                              Committee on Human Research Protections.                nih.gov.                                              restimulation-induced cell death (RICD)
                                              [FR Doc. 2018–20676 Filed 9–21–18; 8:45 am]             (Catalogue of Federal Domestic Assistance             could cure the disease and overcome the
                                              BILLING CODE 4150–36–P                                  Program Nos. 93.846, Arthritis,                       fatal side effects of current therapies.


                                         VerDate Sep<11>2014   17:40 Sep 21, 2018   Jkt 244001   PO 00000   Frm 00046   Fmt 4703   Sfmt 4703   E:\FR\FM\24SEN1.SGM   24SEN1



Document Created: 2018-09-22 00:33:02
Document Modified: 2018-09-22 00:33:02
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesOctober 10, 2018.
FR Citation83 FR 48319 

2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR